SERA News and Press, Sera Prognostics Inc. From 03/29/22

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS PR Newswire SALT LAKE CITY , March 29, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by ...

Gainers: NeuroSense Therapeutics (NRSN) +289%. Yumanity Therapeutics (YMTX) +36%. Dermata Therapeutics (SERA) +30%. Sera Prognostics (DRMA) +21%. Creative Medical Technology Holdings (CELZ) +20%. Losers: Vallon Pharmaceuticals (VLON) -70%. Connect Biopharma Holdings (CNTB) -22%. Imm...

Gainers: Sera Prognostics (SERA) +10%. Harte-Hanks  (HHS) +7%. Precigen (PGEN) +5%. Greenidge Generation Holdings  (GREE) +5%. IGM Biosciences (IGMS) +5%. Losers: Connect Biopharma Holdings Limited (CNTB) -17%. Arhaus (ARHS) -5%. Fluent (FLNT) -5%. Marinus Pharmaceuticals ...

Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting PR Newswire SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company...

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29 PR Newswire SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SER...

The following slide deck was published by Sera Prognostics, Inc. in conjunction with this event. For further details see: Sera Prognostics (SERA) Investor Presentation - Slideshow

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES PR Newswire SALT LAKE CITY , March 3, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by prov...

SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE PR Newswire SALT LAKE CITY , Feb. 17, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal...

SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES PR Newswire SALT LAKE CITY , Feb. 7, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health b...

Sera Prognostics (SERA +3.7%) has signed an agreement with MultiPlan to join its PHCS and MultiPlan Networks to widen the patient access to the company’s PreTRM Test, a blood-based biomarker test to predict spontaneous preterm birth. PreTRM Test allows the clinicians to accurately iden...